Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.71 |
| ▸ | QDPR | P09417 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL19989664 | 0.87 | SIGMAR1 (0.67) | HTR2CQDPRSIGMAR1P2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL30182435 | 0.85 | QDPR (0.53) | HTR2CQDPRSIGMAR1P2RY14NAMPT | |
| SCHEMBL1199051 | 0.84 | HTR2C (1.00) | HTR2CQDPRSIGMAR1NAMPTHTR2A | |
| Trifluoroacetic Acid SCHEMBL29968193 | 0.83 | HTR2C (0.48) | HTR2CQDPRSIGMAR1P2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL7408751 | 0.83 | HTR2C (0.48) | HTR2CQDPRSIGMAR1P2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL29749858 | 0.83 | QDPR (0.50) | HTR2CQDPRSIGMAR1P2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL16228956 | 0.82 | SIGMAR1 (0.51) | HTR2CQDPRSIGMAR1P2RY14NAMPT | |
| Hydrochloric Acid SCHEMBL25217174 | 0.82 | HTR2C (1.00) | HTR2CQDPRSIGMAR1HTR2AHTR7 | |
| Trifluoroacetic Acid SCHEMBL1198632 | 0.81 | SIGMAR1 (0.50) | HTR2CQDPRSIGMAR1P2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL22265884 | 0.77 | SIGMAR1 (0.58) | HTR2CQDPRSIGMAR1P2RY14NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077387-B1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-20 | — | — | EP | disclosed |
| US-9562035-B2 | Benzamide derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | disclosed |
| EP-3077387-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica, N.V. (BE) | 2016-10-12 | — | — | EP | disclosed |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | disclosed |
| WO-2015084606-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, FABP1, BCL3 | HTR2C 2477/4885QDPR 956/4885SIGMAR1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.